HISTAMINE RECEPTOR ANTAGONISTS & GASTRIC CARIDA/LOWER ESOPHAGUS ADENOCARCINOMA

组胺受体拮抗剂

• 批准号: 6268958
• 负责人: LESLIE BERNSTEIN
• 金额: $ 9.65万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-04-01 至 1999-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6268958
• 关键词: adenocarcinoma; alcoholic beverage consumption; antiinflammatory agents; antiulcer drug; aspirin; caffeine; cancer registry /resource; cancer risk; dosage; drug administration rate /duration; drug adverse effect; drug related neoplasm /cancer; esophagus neoplasm; gastric acid; human subject; iatrogenic disease; interview; medical records; neoplasm /cancer epidemiology; nutrition related neoplasm /cancer; nutrition related tag; occupational hazard; questionnaires; statistics /biometry; stomach neoplasms; tobacco abuse

Gastric cancer incidence overall has declined in the U.S. during the past 50 years but the incidence of adenocarcinoma of the gastric cardia and lower esophagus has recently substantially increased. Compared to gastric and esophageal cancer overall, adenocarcinoma of the gastric cardia and lower esophagus is characterized by a high male to female ratio and is relatively more common in whites. Experimental and clinical evidence suggest that duodenal gastric or esophageal reflux may play an etiologic role in proximal gastric carcinogenesis. Histamine2 (H2)-receptor antagonists (H2-blockers) were introduced in the mid-1970s and have become the treatment of choice for peptic ulcer disease and gastroesophageal reflux disorders. H2-blockers are potentially involved in gastric carcinogenesis. These drugs alter gastric acid production, increasing gastric pH and allowing reflux of alkaline duodenal refluxate into the proximal stomach and lower esophagus. Furthermore these drugs can be nitrosated to form mutagenic N-nitroso compounds. We propose a population-based case-control study to evaluate the role of this category of drugs (including possible effects of age at first use, dose, duration of use, latency and condition for which H2-blockers were prescribed) as well as other possible risk factors (e.g., use of other categories of drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, prior benign conditions of the stomach and esophagus, smoking and alcohol use, dietary factors, and Helicobacter pylori infection) in the etiology of adenocarcinoma of the gastric cardia/lower esophagus. Cases will be identified by the population-based Cancer Surveillance Program Core Resource over 4.5 years. Controls will be neighborhood controls matched 2:1 with cases on age, race, and sex. A total of 410 case-control triplets will be interviewed during the course of this study.

过去，美国胃癌发病率总体有所下降 50年来贲门腺癌发病率与 下食道最近明显增大。 与胃相比 总体而言，食管癌、贲门腺癌和 下食管的特点是男女比例较高， 相对来说，在白人中更为常见。 实验和临床证据表明十二指肠胃或 食管反流可能在近端胃的病因学中发挥作用 致癌作用。 组胺 2 (H2) 受体拮抗剂（H2 阻滞剂） 于 20 世纪 70 年代中期推出，并已成为以下疾病的首选治疗方法： 消化性溃疡病和胃食管反流病。 H2 阻滞剂 可能参与胃癌的发生。 这些药物会改变 胃酸的产生，增加胃的pH值并允许胃酸反流 碱性十二指肠反流至近端胃和下食管。 此外，这些药物可以被亚硝化形成诱变的 N-亚硝基 化合物。 我们提出一项基于人群的病例对照研究来评估 此类药物（包括首次使用时年龄可能产生的影响， H2 阻滞剂的剂量、使用持续时间、潜伏期和条件 规定）以及其他可能的风险因素（例如，使用其他 药物类别，例如非甾体抗炎药 (NSAID) 包括阿司匹林、先前胃部和食道的良性状况， 吸烟和饮酒、饮食因素和幽门螺杆菌 感染）在贲门/下胃腺癌的病因学中 食管。 病例将由基于人群的癌症识别 监督计划核心资源超过 4.5 年。 控制措施将是 邻里控制与年龄、种族和性别的案例进行 2:1 匹配。 一个 总共 410 名病例对照三胞胎将在调查过程中接受采访 这项研究。